Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Bally
Julia Bally, Lyon FR
| Patent application number | Description | Published |
|---|---|---|
| 20090328249 | Transplastomic Plants Expressing Lumen-Targeted Protein - The present invention relates to nucleic acid sequences and methods useful in targeting a recombinant protein encoded by a transgene integrated into the chloroplast genome to the thylakoid lumen of chloroplast, whereby said nucleic acid sequences encode bacterial signal peptides. The invention also relates to means and methods for expressing a disulfide-bond containing protein of interest in a transplastomic plant cell. | 12-31-2009 |
Marcel Bally, Bowen Island CA
| Patent application number | Description | Published |
|---|---|---|
| 20080213183 | Free or Liposomal Gemcitabine Alone or in Combination with Free or Liposomal Idarubicin - The use of the maximum tolerated dose (MTD) of individual drugs to determine appropriate administration ratios of drugs for combination therapy, wherein the ratios of drugs are fixed based on the same percentage of the MTD for each drug. Furthermore, antineoplastic compositions comprising liposomal encapsulated gemcitabine alone or in combination with free or liposomal encapsulated antineoplastic agents, such as idarubicin, irinotecan, etopside, cisplatin, cyclophosphamide, doxorubicin, or vincristine are diclosed. | 09-04-2008 |
| 20080286350 | Formulation of Multivalent Antibody Constructs and Use of Same for Cancer Therapy - The invention relates to the formation of multivalent antibody constructs for testing and therapeutic purposes. In one embodiment the constructs consist of antibodies or antibody fragments conjugated to liposomes. The constructs are employed in a cell-based in vitro assay for comparing the therapeutic activity of antibodies or antibody fragments in multivalent form to the same antibodies or fragments in bivalent, free form. The assay is useful for identifying antibodies having potential in vivo activity. Selected antibodies may then be tested in an animal model of a disease state, such as cancer or an autoimmune disorder. Co-delivery of antibodies and chemotherapeutics may also be investigated. In accordance with the invention, a significant enhancement in the activity of antibodies such as trastuzumab and rituximab was observed when these antibodies were presented in the multivalent liposomal form. Key cell survival signaling molecules were down-regulated upon treatment with the multivalent liposomal antibody construct. The invention demonstrates the potential of liposome technology to enhance the therapeutic effect of antibodies via a mechanism that modulates cell survival, likely through clustering of target/antibody complex. | 11-20-2008 |
| 20090028931 | Liposomal compositions for parenteral delivery of agents - The invention provides methods and compositions for loading an agent, such as econazole, onto a liposome for parental delivery. The loading of the agent into a liposome comprises combining the agent with a micelle-forming compound to form a micelle including the agent, where the agent is releasable from the micelle-forming compound, and adding the micelle to the liposome, where the micelle combines with the liposome such that the agent is loaded into the liposome to form a loaded liposome. The methods are suitable for the loading of poorly soluble agents onto liposome. | 01-29-2009 |
Marcel Bally, Bowen Islnd CA
| Patent application number | Description | Published |
|---|---|---|
| 20110165225 | Modified Drugs for Use in Liposomal Nanoparticles - Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags. | 07-07-2011 |
Marcel B. Bally, Bowen Island CA
| Patent application number | Description | Published |
|---|---|---|
| 20100041152 | METHODS FOR ENCAPSULATING PLASMIDS IN LIPID BILAYERS - Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable. | 02-18-2010 |
Uwe Bally, Erlangen DE
| Patent application number | Description | Published |
|---|---|---|
| 20100054513 | Hearing aid with an attenuation element - A shielding element and a decoupling element are integrated into a combined attenuation element. The shielding element may be a shielding foil, preferably made of copper. The attenuation element may include a flexible backing foil, preferably a plastic backing foil which supports the shielding foil. It may also include an adhesive layer with which the electronic component is affixed to a housing. The physical properties of all elements of the attenuation element are attuned to one another such that it simultaneously attenuates both electromagnetic alternating fields as well as mechanical oscillations. | 03-04-2010 |